Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod

Zuzana Berrong, Mikayel Mkrtichyan, Shamim Ahmad, Mason Webb, Eslam Mohamed, Grigori Okoev, Adelaida Matevosyan, Rajeev Kumar Shrimali, Rasha Abu Eid, Scott Hammond, John Edward Janik, Samir N. Khleif

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here, we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60% of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40 and (ii) a decrease of IDO enzyme activity produced by nontumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalCancer Immunology Research
Volume6
Issue number2
DOIs
StatePublished - Feb 2018

Fingerprint

Antigens
Neoplasms
Vaccines
Immunotherapy
Indoleamine-Pyrrole 2,3,-Dioxygenase
T-Lymphocytes
Cancer Vaccines
Tumor Microenvironment
1-methyltryptophan
Histocompatibility Antigens Class II
Immunosuppressive Agents
Immunity
Therapeutics
Enzymes

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Berrong, Z., Mkrtichyan, M., Ahmad, S., Webb, M., Mohamed, E., Okoev, G., ... Khleif, S. N. (2018). Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod. Cancer Immunology Research, 6(2), 201-208. https://doi.org/10.1158/2326-6066.CIR-17-0223

Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod. / Berrong, Zuzana; Mkrtichyan, Mikayel; Ahmad, Shamim; Webb, Mason; Mohamed, Eslam; Okoev, Grigori; Matevosyan, Adelaida; Shrimali, Rajeev Kumar; Eid, Rasha Abu; Hammond, Scott; Janik, John Edward; Khleif, Samir N.

In: Cancer Immunology Research, Vol. 6, No. 2, 02.2018, p. 201-208.

Research output: Contribution to journalArticle

Berrong, Z, Mkrtichyan, M, Ahmad, S, Webb, M, Mohamed, E, Okoev, G, Matevosyan, A, Shrimali, RK, Eid, RA, Hammond, S, Janik, JE & Khleif, SN 2018, 'Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod', Cancer Immunology Research, vol. 6, no. 2, pp. 201-208. https://doi.org/10.1158/2326-6066.CIR-17-0223
Berrong, Zuzana ; Mkrtichyan, Mikayel ; Ahmad, Shamim ; Webb, Mason ; Mohamed, Eslam ; Okoev, Grigori ; Matevosyan, Adelaida ; Shrimali, Rajeev Kumar ; Eid, Rasha Abu ; Hammond, Scott ; Janik, John Edward ; Khleif, Samir N. / Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod. In: Cancer Immunology Research. 2018 ; Vol. 6, No. 2. pp. 201-208.
@article{fea0bf57b53e46858e3230916f8452df,
title = "Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod",
abstract = "Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here, we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60{\%} of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40 and (ii) a decrease of IDO enzyme activity produced by nontumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.",
author = "Zuzana Berrong and Mikayel Mkrtichyan and Shamim Ahmad and Mason Webb and Eslam Mohamed and Grigori Okoev and Adelaida Matevosyan and Shrimali, {Rajeev Kumar} and Eid, {Rasha Abu} and Scott Hammond and Janik, {John Edward} and Khleif, {Samir N.}",
year = "2018",
month = "2",
doi = "10.1158/2326-6066.CIR-17-0223",
language = "English (US)",
volume = "6",
pages = "201--208",
journal = "Cancer Immunity",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Antigen-Specific antitumor responses induced by OX40 agonist are enhanced by the ido inhibitor indoximod

AU - Berrong, Zuzana

AU - Mkrtichyan, Mikayel

AU - Ahmad, Shamim

AU - Webb, Mason

AU - Mohamed, Eslam

AU - Okoev, Grigori

AU - Matevosyan, Adelaida

AU - Shrimali, Rajeev Kumar

AU - Eid, Rasha Abu

AU - Hammond, Scott

AU - Janik, John Edward

AU - Khleif, Samir N.

PY - 2018/2

Y1 - 2018/2

N2 - Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here, we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60% of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40 and (ii) a decrease of IDO enzyme activity produced by nontumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.

AB - Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanisms. Successful cancer immunotherapy requires targeting these inhibitory mechanisms along with enhancement of antigen-specific immune responses to promote sustained tumor-specific immunity. Here, we evaluated the effect of indoximod, an inhibitor of the immunosuppressive indoleamine-(2,3)-dioxygenase (IDO) pathway, on antitumor efficacy of anti-OX40 agonist in the context of vaccine in the IDO TC-1 tumor model. We demonstrate that although the addition of anti-OX40 to the vaccine moderately enhances therapeutic efficacy, incorporation of indoximod into this treatment leads to enhanced tumor regression and cure of established tumors in 60% of treated mice. We show that the mechanisms by which the IDO inhibitor leads to this therapeutic potency include (i) an increment of vaccine-induced tumor-infiltrating effector T cells that is facilitated by anti-OX40 and (ii) a decrease of IDO enzyme activity produced by nontumor cells within the tumor microenvironment that results in enhancement of the specificity and the functionality of vaccine-induced effector T cells. Our findings suggest a translatable strategy to enhance the overall efficacy of cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85041924598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041924598&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-17-0223

DO - 10.1158/2326-6066.CIR-17-0223

M3 - Article

AN - SCOPUS:85041924598

VL - 6

SP - 201

EP - 208

JO - Cancer Immunity

JF - Cancer Immunity

SN - 2326-6066

IS - 2

ER -